• Vaccine Name: B. anthracis rPA Vaccine with Rehydragel HPA adjuvant
• Target Pathogen: Bacillus anthracis
• Target Disease: Anthrax
• Vaccine Ontology ID: VO_0004223
• Type: Subunit vaccine
• Status: Research
• Antigen: purified rPA (Rhie et al., 2005).
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001311
• Immunization Route: Intramuscular injection (i.m.)

Guinea pig Response

• Host Strain: Hartley
• Vaccination Protocol: Groups of female Hartley guinea pigs (Damul Science, Korea) weighing 300–320 g were immunized by intramuscular injection on days 0, 14, and 28 with 50 μg of the purified rPA. rPA was dissolved in 500 μl PBS containing Rehydragel HPA (alum hydroxide fluid gel, 250 μg; Reheis Inc., USA), according to the manufacturer's protocol. Phosphate-buffered saline (PBS) was used as a negative control (Rhie et al., 2005).
• Challenge Protocol: Fourteen days after the third immunization, the guinea pigs were challenged with 100 LD50 of B. anthracis ATCC14578 spores by intramuscular injection. After injection with B. anthracis spores, guinea pigs were observed for a period of 14 days. Animals surviving for 14 days after the challenge were considered survivors (Rhie et al., 2005).
• Efficacy: Guinea pigs immunized with rPA + Rehydragel HPA had 100% survival rate to challenge with B. anthracis ATCC14578 spores (Rhie et al., 2005).